Selank and Semax may appear together in research discussions, but a shared category or similar-looking name does not make them the same material. A useful comparison focuses on residue order and the exact offered structure. The purchasing outcome should be two clearly defined lines, not a combined nickname that leaves substitution decisions to the supplier.
Put the sequence beside each catalog name
The GSRS Selank record gives TKPRPGP. A PubChem Semax-related record records MEHFPGP notation. These are different residue strings, despite the shared PGP ending. Reference records help frame identity questions; an entry in a government substance database is not a statement of marketing approval, clinical suitability or supplier batch conformity.
Use the comparison to prevent substitution
Copy the complete intended sequence into each request and keep the catalog URL with it. The table shows the distinct first four residues rather than presenting one item as a replacement for the other. If both are requested for a project, assign separate line identifiers, quantities and document references. A quotation that combines the names with a slash should be clarified before the buyer accepts a price or container count.
| Material | Reference sequence | Practical distinction |
|---|---|---|
| Selank | TKPRPGP | First four residues TKPR |
| Semax | MEHFPGP | First four residues MEHF |
| Shared ending | PGP | Shared segment does not establish equivalence |
| Modified variant | Expanded structure required | Do not inherit parent documentation |
| Two-material order | Two independent line identifiers | Amounts and evidence remain separate |
Treat modified variants as separate structures
Ask whether the offered item includes terminal acetylation, amidation or another modification. A prefix or suffix in a listing may indicate an actual structural change, not decorative marketing text. Request the expanded structure and do not automatically assign a parent peptide’s reference record or report to the variant. Keep the supplied salt or counterion field separate from covalent terminal modifications so the laboratory can review each difference accurately.
Do not transfer documents between the two lines
Each report should identify the sample it addresses and connect to the relevant offered material. A Selank example report is not Semax evidence, and the reverse is also true. Compare the analytical scope with the exact requested identity. Keep quantity basis and purity fields separate. If the supplier has not assigned lots yet, mark the records as examples and request actual material-linked documentation before the receiving review is closed.
Finish with a comparison card, not an effects ranking
For each line, record sequence, termini, supplied form, amount basis, containers and evidence status. This supports an accurate inquiry and a repeat-order check. It does not rank biological effects, recommend combining materials or establish suitability for personal use. If a proposal changes one line, update that card only and retain the earlier version. Another reviewer should be able to identify the change without reconstructing the entire email conversation.
Before closing this review
- Separate sequences have separate order lines.
- Shared residues do not establish equivalence.
- Modified variants have expanded structures.
- Database registration is not an approval claim.
Continue with review the relevant catalog record; prepare a precise material inquiry. Save the relevant product or guide link alongside the written response so another reviewer can reconstruct the decision.
Editorial scope: research-material procurement and document review. Not medical guidance, dosing instructions or a claim of suitability for human use. Requirements and availability must be confirmed for the quoted material.
